Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 948 entries
Sorted by: Best Match Show Resources per page
Characterization of CTX-M-Type Extend-Spectrum β-Lactamase Producing Klebsiella spp. in Kashan, Iran.

Jundishapur journal of microbiology

Afzali H, Firoozeh F, Amiri A, Moniri R, Zibaei M.
PMID: 26587221
Jundishapur J Microbiol. 2015 Oct 26;8(10):e27967. doi: 10.5812/jjm.27967. eCollection 2015 Oct.

CONTEXT: The CTX-M family consists of more than 50 β-lactamases, which are grouped on the basis of sequences into five subtypes including CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25.OBJECTIVES: The current study aimed to detect subtypes of CTX-M extended-spectrum β-lactamases...

Cite
Afzali H, Firoozeh F, Amiri A, et al. Characterization of CTX-M-Type Extend-Spectrum β-Lactamase Producing Klebsiella spp. in Kashan, Iran. Jundishapur J Microbiol. 2015;8(10):e27967doi: 10.5812/jjm.27967.
Afzali, H., Firoozeh, F., Amiri, A., Moniri, R., & Zibaei, M. (2015). Characterization of CTX-M-Type Extend-Spectrum β-Lactamase Producing Klebsiella spp. in Kashan, Iran. Jundishapur journal of microbiology, 8(10), e27967. https://doi.org/10.5812/jjm.27967
Afzali, Hasan, et al. "Characterization of CTX-M-Type Extend-Spectrum β-Lactamase Producing Klebsiella spp. in Kashan, Iran." Jundishapur journal of microbiology vol. 8,10 (2015): e27967. doi: https://doi.org/10.5812/jjm.27967
Afzali H, Firoozeh F, Amiri A, Moniri R, Zibaei M. Characterization of CTX-M-Type Extend-Spectrum β-Lactamase Producing Klebsiella spp. in Kashan, Iran. Jundishapur J Microbiol. 2015 Oct 26;8(10):e27967. doi: 10.5812/jjm.27967. eCollection 2015 Oct. PMID: 26587221; PMCID: PMC4644347.
Copy Download .nbib Format: NLM
Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia.

Journal of the Pediatric Infectious Diseases Society

Fisher BT, Sammons JS, Li Y, de Blank P, Seif AE, Huang YS, Kavcic M, Klieger S, Harris T, Torp K, Rheam D, Shah A, Aplenc R.
PMID: 26625453
J Pediatric Infect Dis Soc. 2014 Dec;3(4):329-35. doi: 10.1093/jpids/piu008. Epub 2014 Feb 16.

BACKGROUND: Antibiotic exposure is common among children with leukemia. However, limited data exist regarding the risk of Clostridium difficile infection (CDI) across anti-pseudomonal β-lactam antibiotics commonly used for fever and neutropenia.METHODS: A multicenter cohort of children with newly diagnosed...

Cite
Fisher BT, Sammons JS, Li Y, et al. Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. J Pediatric Infect Dis Soc. 2014;3(4):329-35doi: 10.1093/jpids/piu008.
Fisher, B. T., Sammons, J. S., Li, Y., de Blank, P., Seif, A. E., Huang, Y. S., Kavcic, M., Klieger, S., Harris, T., Torp, K., Rheam, D., Shah, A., & Aplenc, R. (2014). Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. Journal of the Pediatric Infectious Diseases Society, 3(4), 329-35. https://doi.org/10.1093/jpids/piu008
Fisher, Brian T, et al. "Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia." Journal of the Pediatric Infectious Diseases Society vol. 3,4 (2014): 329-35. doi: https://doi.org/10.1093/jpids/piu008
Fisher BT, Sammons JS, Li Y, de Blank P, Seif AE, Huang YS, Kavcic M, Klieger S, Harris T, Torp K, Rheam D, Shah A, Aplenc R. Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. J Pediatric Infect Dis Soc. 2014 Dec;3(4):329-35. doi: 10.1093/jpids/piu008. Epub 2014 Feb 16. PMID: 26625453; PMCID: PMC4854370.
Copy Download .nbib Format: NLM
ISPpu22, a novel insertion sequence in the oprD porin gene of a carbapenem-resistant Pseudomonas aeruginosa isolate from a burn patient in Tehran, Iran.

Iranian journal of microbiology

Kalantar-Neyestanaki D, Emaneini M, Jabalameli F, Taherikalani M, Mirsalehian A.
PMID: 26719780
Iran J Microbiol. 2015 Oct;7(5):247-50.

BACKGROUND AND OBJECTIVES: The oprD mutation and AmpC overproduction are the main mechanisms of intrinsic resistance to carbapenems such as imipenem and meropenem in Pseudomonas aeruginosa.MATERIALS AND METHODS: In this study, we investigated intrinsic resistance to carbapenems including mutation...

Cite
Kalantar-Neyestanaki D, Emaneini M, Jabalameli F, et al. ISPpu22, a novel insertion sequence in the oprD porin gene of a carbapenem-resistant Pseudomonas aeruginosa isolate from a burn patient in Tehran, Iran. Iran J Microbiol. 2015;7(5):247-50
Kalantar-Neyestanaki, D., Emaneini, M., Jabalameli, F., Taherikalani, M., & Mirsalehian, A. (2015). ISPpu22, a novel insertion sequence in the oprD porin gene of a carbapenem-resistant Pseudomonas aeruginosa isolate from a burn patient in Tehran, Iran. Iranian journal of microbiology, 7(5), 247-50.
Kalantar-Neyestanaki, Davood, et al. "ISPpu22, a novel insertion sequence in the oprD porin gene of a carbapenem-resistant Pseudomonas aeruginosa isolate from a burn patient in Tehran, Iran." Iranian journal of microbiology vol. 7,5 (2015): 247-50.
Kalantar-Neyestanaki D, Emaneini M, Jabalameli F, Taherikalani M, Mirsalehian A. ISPpu22, a novel insertion sequence in the oprD porin gene of a carbapenem-resistant Pseudomonas aeruginosa isolate from a burn patient in Tehran, Iran. Iran J Microbiol. 2015 Oct;7(5):247-50. PMID: 26719780; PMCID: PMC4695505.
Copy Download .nbib Format: NLM
Spectrum and Sensitivity of Bacterial Keratitis Isolates in Auckland.

Journal of ophthalmology

Marasini S, Swift S, Dean SJ, Ormonde SE, Craig JP.
PMID: 27213052
J Ophthalmol. 2016;2016:3769341. doi: 10.1155/2016/3769341. Epub 2016 Apr 26.

Background. The bacteria isolated from severe cases of keratitis and their antibiotic sensitivity are recognised to vary geographically and over time. Objectives. To identify the most commonly isolated bacteria in keratitis cases admitted over a 24-month period to a...

Cite
Marasini S, Swift S, Dean SJ, et al. Spectrum and Sensitivity of Bacterial Keratitis Isolates in Auckland. J Ophthalmol. 2016;2016:3769341doi: 10.1155/2016/3769341.
Marasini, S., Swift, S., Dean, S. J., Ormonde, S. E., & Craig, J. P. (2016). Spectrum and Sensitivity of Bacterial Keratitis Isolates in Auckland. Journal of ophthalmology, 20163769341. https://doi.org/10.1155/2016/3769341
Marasini, S, et al. "Spectrum and Sensitivity of Bacterial Keratitis Isolates in Auckland." Journal of ophthalmology vol. 2016 (2016): 3769341. doi: https://doi.org/10.1155/2016/3769341
Marasini S, Swift S, Dean SJ, Ormonde SE, Craig JP. Spectrum and Sensitivity of Bacterial Keratitis Isolates in Auckland. J Ophthalmol. 2016;2016:3769341. doi: 10.1155/2016/3769341. Epub 2016 Apr 26. PMID: 27213052; PMCID: PMC4861789.
Copy Download .nbib Format: NLM
Pseudomonas as trespassers in diabetic foot infections: More questions and fewer answers.

JPMA. The Journal of the Pakistan Medical Association

Najjad MK, Idrees Z, Zamir M, Zeeshan S, Shah SA.
PMID: 25989756
J Pak Med Assoc. 2014 Dec;64(12):S112-5.

OBJECTIVE: To assess microbiological isolates from diabetic foot ulcers presented at a tertiary care teaching hospital.METHODS: The prospective observational study was conducted at department of Orthopaedics, Liaquat National Hospital Karachi, from January 2009 to October 2011, and comprised patients...

Cite
Najjad MK, Idrees Z, Zamir M, et al. Pseudomonas as trespassers in diabetic foot infections: More questions and fewer answers. J Pak Med Assoc. 2014;64(12):S112-5
Najjad, M. K., Idrees, Z., Zamir, M., Zeeshan, S., & Shah, S. A. (2014). Pseudomonas as trespassers in diabetic foot infections: More questions and fewer answers. JPMA. The Journal of the Pakistan Medical Association, 64(12), S112-5.
Najjad, Muhammad Kazim Rahim, et al. "Pseudomonas as trespassers in diabetic foot infections: More questions and fewer answers." JPMA. The Journal of the Pakistan Medical Association vol. 64,12 (2014): S112-5.
Najjad MK, Idrees Z, Zamir M, Zeeshan S, Shah SA. Pseudomonas as trespassers in diabetic foot infections: More questions and fewer answers. J Pak Med Assoc. 2014 Dec;64(12):S112-5. PMID: 25989756.
Copy Download .nbib Format: NLM
Estimation of outer membrane permeability of carbapenem antibiotics to Pseudomonas aeruginosa.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Iyobe S, Watanabe M, Mitsuhashi S, Inoue M.
PMID: 11810510
J Infect Chemother. 1999 Sep;5(3):168-170. doi: 10.1007/s101560050028.

The outer membrane permeability of carbapenems (imipenem [IPM], panipenem [PAPM], meropenem [MEPM], and biapenem [BIPM]) and ceftazidime (CAZ) to Pseudomonas aeruginosa was determined by the Zimmermann and Rosselet method. The permeability coefficients of beta-lactams tested at 50 &mgr;M concentration...

Cite
Iyobe S, Watanabe M, Mitsuhashi S, et al. Estimation of outer membrane permeability of carbapenem antibiotics to Pseudomonas aeruginosa. J Infect Chemother. 1999;5(3):168-170doi: 10.1007/s101560050028.
Iyobe, S., Watanabe, M., Mitsuhashi, S., & Inoue, M. (1999). Estimation of outer membrane permeability of carbapenem antibiotics to Pseudomonas aeruginosa. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 5(3), 168-170. https://doi.org/10.1007/s101560050028
Iyobe, S., et al. "Estimation of outer membrane permeability of carbapenem antibiotics to Pseudomonas aeruginosa." Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy vol. 5,3 (1999): 168-170. doi: https://doi.org/10.1007/s101560050028
Iyobe S, Watanabe M, Mitsuhashi S, Inoue M. Estimation of outer membrane permeability of carbapenem antibiotics to Pseudomonas aeruginosa. J Infect Chemother. 1999 Sep;5(3):168-170. doi: 10.1007/s101560050028. PMID: 11810510.
Copy Download .nbib Format: NLM
Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital.

Annals of clinical microbiology and antimicrobials

Gonlugur U, Bakici MZ, Ozdemir L, Akkurt I, Icagasioglu S, Gultekin F.
PMID: 12665428
Ann Clin Microbiol Antimicrob. 2003 Mar 07;2:5. doi: 10.1186/1476-0711-2-5.

BACKGROUND: Lower respiratory tract infections due to Pseudomonas aeruginosa have a high mortality rate. Antibacterial activity of various antibiotics against P. aeruginosa isolated from each hospital depends on the variety or amount of antibiotics used in each hospital.METHOD: A...

Cite
Gonlugur U, Bakici MZ, Ozdemir L, et al. Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital. Ann Clin Microbiol Antimicrob. 2003;2:5doi: 10.1186/1476-0711-2-5.
Gonlugur, U., Bakici, M. Z., Ozdemir, L., Akkurt, I., Icagasioglu, S., & Gultekin, F. (2003). Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital. Annals of clinical microbiology and antimicrobials, 25. https://doi.org/10.1186/1476-0711-2-5
Gonlugur, Ugur, et al. "Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital." Annals of clinical microbiology and antimicrobials vol. 2 (2003): 5. doi: https://doi.org/10.1186/1476-0711-2-5
Gonlugur U, Bakici MZ, Ozdemir L, Akkurt I, Icagasioglu S, Gultekin F. Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital. Ann Clin Microbiol Antimicrob. 2003 Mar 07;2:5. doi: 10.1186/1476-0711-2-5. PMID: 12665428; PMCID: PMC152644.
Copy Download .nbib Format: NLM
Piperacillin/Tazobactam: Evaluation of Its In vitro Activity against Bacteria Isolated in Two Brazilian Hospitals and an Overview of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Potential.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Sader HS, Ferreira AT, Tosin I, Gales AC, Keim LS, Carbadillo JM, Mello SJ, Tavares W.
PMID: 11103015
Braz J Infect Dis. 1998 Oct;2(5):241-255.

Piperacillin/tazobactam is a highly active antibiotic against most clinically important species of Gram-negative and positive bacteria, including anaerobes. It has never been used or tested against bacteria isolated in Brazil. In this article we report the in vitro activity...

Cite
Sader HS, Ferreira AT, Tosin I, et al. Piperacillin/Tazobactam: Evaluation of Its In vitro Activity against Bacteria Isolated in Two Brazilian Hospitals and an Overview of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Potential. Braz J Infect Dis. 1998;2(5):241-255
Sader, H. S., Ferreira, A. T., Tosin, I., Gales, A. C., Keim, L. S., Carbadillo, J. M., Mello, S. J., & Tavares, W. (1998). Piperacillin/Tazobactam: Evaluation of Its In vitro Activity against Bacteria Isolated in Two Brazilian Hospitals and an Overview of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Potential. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2(5), 241-255.
Sader, et al. "Piperacillin/Tazobactam: Evaluation of Its In vitro Activity against Bacteria Isolated in Two Brazilian Hospitals and an Overview of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Potential." The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases vol. 2,5 (1998): 241-255.
Sader HS, Ferreira AT, Tosin I, Gales AC, Keim LS, Carbadillo JM, Mello SJ, Tavares W. Piperacillin/Tazobactam: Evaluation of Its In vitro Activity against Bacteria Isolated in Two Brazilian Hospitals and an Overview of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Potential. Braz J Infect Dis. 1998 Oct;2(5):241-255. PMID: 11103015.
Copy Download .nbib Format: NLM
Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Sader HS, Jones RN, Winokur PL, Pfaller MA, Doern GV, Barrett T.
PMID: 11856291
Clin Microbiol Infect. 1999 Aug;5(8):478-487. doi: 10.1111/j.1469-0691.1999.tb00177.x.

OBJECTIVE: To evaluate the antimicrobial susceptibility patterns among 469 pathogens isolated as a significant cause of urinary tract infections in 10 Latin American medical centers. METHODS: Consecutively collected isolates were susceptibility tested by broth microdilution methods, and selected isolates...

Cite
Sader HS, Jones RN, Winokur PL, et al. Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997). Clin Microbiol Infect. 1999;5(8):478-487doi: 10.1111/j.1469-0691.1999.tb00177.x.
Sader, H. S., Jones, R. N., Winokur, P. L., Pfaller, M. A., Doern, G. V., Barrett, T. (1999). Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997). Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 5(8), 478-487. https://doi.org/10.1111/j.1469-0691.1999.tb00177.x
Sader, Helio S., et al. "Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997)." Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases vol. 5,8 (1999): 478-487. doi: https://doi.org/10.1111/j.1469-0691.1999.tb00177.x
Sader HS, Jones RN, Winokur PL, Pfaller MA, Doern GV, Barrett T. Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997). Clin Microbiol Infect. 1999 Aug;5(8):478-487. doi: 10.1111/j.1469-0691.1999.tb00177.x. PMID: 11856291.
Copy Download .nbib Format: NLM
Cytotoxicity towards human endothelial cells, induced by neutrophil myeloperoxidase: protection by ceftazidime.

Mediators of inflammation

Mathy-Hartert M, Deby-Dupont G, Deby C, Jadoul L, Vandenberghe A, Lamy M.
PMID: 18475677
Mediators Inflamm. 1995;4(6):437-43. doi: 10.1155/S0962935195000706.

We investigated the effects of the antibiotic ceftazidime (CAZ) on the cytolytic action of the neutrophil myeloperoxidase-hydrogen peroxide-chloride anion system (MPO/H(2)O(2)/Cl(-)). In this system, myeloperoxidase catalyses the conversion of H(2)O(2) and CI(-) to the cytotoxic agent HOCl. Stimulated neutrophils...

Cite
Mathy-Hartert M, Deby-Dupont G, Deby C, et al. Cytotoxicity towards human endothelial cells, induced by neutrophil myeloperoxidase: protection by ceftazidime. Mediators Inflamm. 1995;4(6):437-43doi: 10.1155/S0962935195000706.
Mathy-Hartert, M., Deby-Dupont, G., Deby, C., Jadoul, L., Vandenberghe, A., & Lamy, M. (1995). Cytotoxicity towards human endothelial cells, induced by neutrophil myeloperoxidase: protection by ceftazidime. Mediators of inflammation, 4(6), 437-43. https://doi.org/10.1155/S0962935195000706
Mathy-Hartert, M, et al. "Cytotoxicity towards human endothelial cells, induced by neutrophil myeloperoxidase: protection by ceftazidime." Mediators of inflammation vol. 4,6 (1995): 437-43. doi: https://doi.org/10.1155/S0962935195000706
Mathy-Hartert M, Deby-Dupont G, Deby C, Jadoul L, Vandenberghe A, Lamy M. Cytotoxicity towards human endothelial cells, induced by neutrophil myeloperoxidase: protection by ceftazidime. Mediators Inflamm. 1995;4(6):437-43. doi: 10.1155/S0962935195000706. PMID: 18475677; PMCID: PMC2365676.
Copy Download .nbib Format: NLM
Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes.

Clinical drug investigation

Rossini F, Pioltelli P, Bolis S, Borin L, Casaroli I, Lanzi E, Maffè P, Parma M, Tripputi P, Pogliani EM.
PMID: 18370498
Clin Drug Investig. 1998;15(5):425-33. doi: 10.2165/00044011-199815050-00007.

To assess the economic outcomes produced when a conventional antibiotic treatment regimen requiring three administrations per day was replaced with a treatment regimen requiring only one daily administration, the efficacy, tolerability and cost of ceftazidime was compared with that...

Cite
Rossini F, Pioltelli P, Bolis S, et al. Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes. Clin Drug Investig. 1998;15(5):425-33doi: 10.2165/00044011-199815050-00007.
Rossini, F., Pioltelli, P., Bolis, S., Borin, L., Casaroli, I., Lanzi, E., Maffè, P., Parma, M., Tripputi, P., & Pogliani, E. M. (1998). Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes. Clinical drug investigation, 15(5), 425-33. https://doi.org/10.2165/00044011-199815050-00007
Rossini, F, et al. "Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes." Clinical drug investigation vol. 15,5 (1998): 425-33. doi: https://doi.org/10.2165/00044011-199815050-00007
Rossini F, Pioltelli P, Bolis S, Borin L, Casaroli I, Lanzi E, Maffè P, Parma M, Tripputi P, Pogliani EM. Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes. Clin Drug Investig. 1998;15(5):425-33. doi: 10.2165/00044011-199815050-00007. PMID: 18370498.
Copy Download .nbib Format: NLM
Extended spectrum beta lactamase (ESBL) mediated resistance to third generation cephalosporins among Klebsiella pneumoniae in Chennai.

Indian journal of medical microbiology

Subha A, Ananthan S.
PMID: 17657040
Indian J Med Microbiol. 2002 Apr-Jun;20(2):92-5.

PURPOSE: To examine the incidence of extended spectrum b lactamase (ESbL) producing strains and multidrug resistant strains of Klebsiella pneumoniae isolated from children between 0-5 years of age.METHODS: Multidrug resistance and ESbL production was studied in a total of...

Cite
Subha A, Ananthan S. Extended spectrum beta lactamase (ESBL) mediated resistance to third generation cephalosporins among Klebsiella pneumoniae in Chennai. Indian J Med Microbiol. 2002;20(2):92-5
Subha, A., & Ananthan, S. (2002). Extended spectrum beta lactamase (ESBL) mediated resistance to third generation cephalosporins among Klebsiella pneumoniae in Chennai. Indian journal of medical microbiology, 20(2), 92-5.
Subha, A, and Ananthan, S. "Extended spectrum beta lactamase (ESBL) mediated resistance to third generation cephalosporins among Klebsiella pneumoniae in Chennai." Indian journal of medical microbiology vol. 20,2 (2002): 92-5.
Subha A, Ananthan S. Extended spectrum beta lactamase (ESBL) mediated resistance to third generation cephalosporins among Klebsiella pneumoniae in Chennai. Indian J Med Microbiol. 2002 Apr-Jun;20(2):92-5. PMID: 17657040.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 948 entries